Patents Assigned to Regeneron Pharmnaceuticals, Inc.
  • Anti-VEGF protein compositions and methods for producing the same
    Patent number: 11098112
    Abstract: The present disclosure pertains to compositions comprising aflibercept and methods for producing such compositions in chemically defined media and using chromatography to reduce amounts of certain aflibercept variants.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: August 24, 2021
    Assignee: Regeneron Pharmnaceuticals, Inc.
    Inventors: Andrew Tustian, Ankit Vartak, Thomas Daly, Erica Pyles, Nisha Palackal